Added to YB: 2025-12-18
Pitch date: 2025-12-15
NXGL [neutral]
NEXGEL, Inc.
+18.87%
current return
Author Info
Byron Street Research is an investment publication featuring a weekly event-driven idea generator, write-ups modeled in the familiar format of sell-side equity research reports, and performance reviews structured as traditional fund factsheets. Sign up for the newsletter.
Company Info
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.
Market Cap
$12.9M
Pitch Price
$1.59
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.07
P/E
-4.21
EV/Sales
1.34
Sector
Health Care Equipment and Supplies
Category
special_situation
Catalyst Watch - NEXGEL, Inc.
NXGL (update): Spinning off Rx drug delivery assets into NexGelRx with external funding. Retains 19.99% equity stake up to $8M investment + 5% perpetual royalty on global Rx rights + exclusive manufacturing contract. Allows participation in high-value Rx opportunities while focusing on consumer health/beauty products without direct funding risk.
Read full article (1 min)